Tirzepatide
DrugAdministered SC
Other names: LY3298176
NCT Number: NCT03940742
The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired liver function compared to healthy participants. The study will last about two months and will include five visits to the study center.
Looking for future studies?
Notify Me18 year–85 year
All sexes
Interventional
Phase 1
Orange County Research Center, Tustin, California, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
All Participants:
Healthy Participants:
Participants with Impaired Liver Function:
Exclusion criteria
All Participants:
Participants with Impaired Liver Function:
Administered SC
Other names: LY3298176
Time frame: Predose, 8, 12, 24, 48, 72, 96, 168 and 336 post dose
Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC[0-∞]) of Tirzepatide.
Time frame: Predose, 8, 12, 24, 48, 72, 96, 168 and 336 post dose
PK: Maximum Observed Drug Concentration (Cmax) of Tirzepatide.
Eli Lilly and Company
Industry
A Single Dose Pharmacokinetic Study of Tirzepatide in Subjects With Varying Degrees of Hepatic Impairment
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06858696
Digestive System Diseases, Hepatic Insufficiency
Montclair, California, United States
View Trial DetailsNCT06957756
Digestive System Diseases, Hepatic Insufficiency
Chandler, Arizona, United States
View Trial DetailsNCT06575959
Digestive System Diseases, Hepatic Impairment
Orlando, Florida, United States
View Trial DetailsNCT05882032
Digestive System Diseases, Healthy
Miami, Florida, United States
View Trial Details